Scarica l'app Stockscreener
11.25
2.60%
-0.30
Dopo l'orario di chiusura:
11.36
0.11
+0.98%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché OCUL Giù?
Forum
Previsione
Ocular Therapeutix Inc Borsa (OCUL) Ultime notizie
Ocular Therapeutix, Inc. (OCUL) Investor Outlook: Unpacking The 109% Potential Upside - DirectorsTalk Interviews
RSI Check: How robust is Star Equity Holdings Inc FDV0 stock financial positionMarket Risk Analysis & Weekly Breakout Opportunity Watchlist - moha.gov.vn
The Technical Signals Behind (OCUL) That Institutions Follow - Stock Traders Daily
OCUL News Today | Why did Ocular Therapeutix stock go down today? - MarketBeat
Ocular Therapeutix (NASDAQ:OCUL) Surprises With Q3 CY2025 Sales - TradingView — Track All Markets
What to keep an eye on in 2026 - Eyes On Eyecare
BofA Bullish on Ocular Therapeutix (OCUL) as AXPAXLI Targets Superiority Label and Faster Regulatory Path in Wet AMD - Finviz
Fat Pitch FinancialsOcular Therapeutix, Inc.Common Stock (Nasdaq:OCUL) Stock Quote - FinancialContent
Ocular Therapeutix announces first patient randomized in HELIOS-3 program - MSN
Ocular Therapeutix Earnings Notes - Trefis
Voya Investment Management LLC Trims Position in Ocular Therapeutix, Inc. $OCUL - MarketBeat
Assenagon Asset Management S.A. Sells 148,100 Shares of Ocular Therapeutix, Inc. $OCUL - MarketBeat
Ocular Therapeutix (NASDAQ:OCUL) Share Price Crosses Above 50 Day Moving AverageWhat's Next? - MarketBeat
Trading Systems Reacting to (OCUL) Volatility - Stock Traders Daily
Revenue per share of Ocular Therapeutix Inc – BER:0OT - TradingView — Track All Markets
Is Ocular Therapeutix (NASDAQ:OCUL) Using Too Much Debt? - 富途牛牛
Aug Action: Is Ocular Therapeutix Inc. (0OT) stock among top earnings playsMarket Sentiment Report & High Yield Stock Recommendations - Улправда
What is the fair value of Ocular Therapeutix Inc. stock nowTrade Volume Report & Long Hold Capital Preservation Plans - ulpravda.ru
Can Ocular Therapeutix Inc. stock hit analyst price targetsMarket Performance Recap & Capital Protection Trade Alerts - ulpravda.ru
Is Ocular Therapeutix Inc. (0OT) stock worth buying before Fed action2025 Top Gainers & Verified Short-Term Plans - ulpravda.ru
Is Ocular Therapeutix Inc. (0OT) stock among top earnings playsMarket Trend Summary & Reliable Breakout Forecasts - Улправда
Volume Summary: What is the fair value of Ocular Therapeutix Inc. stock now - ulpravda.ru
Can Ocular Therapeutix Inc. (0OT) stock retain market dominanceEarnings Recap Summary & Weekly Stock Performance Updates - DonanımHaber
How Ocular Therapeutix Inc. stock reacts to job market dataWeekly Trading Summary & Real-Time Buy Signal Alerts - DonanımHaber
What makes Ocular Therapeutix Inc. stock attractive to growth funds2025 Market WrapUp & Real-Time Market Sentiment Reports - DonanımHaber
Why analysts raise outlook for Ocular Therapeutix Inc. (0OT) stock2025 Pullback Review & Community Trade Idea Sharing Platform - Улправда
Ocular Therapeutix (OCUL) Is Down 10.9% After Pivoting AXPAXLI To Single-Trial NDA Pathway – Has The Bull Case Changed? - simplywall.st
Is Ocular Therapeutix Inc. stock in correction or buying zoneQuarterly Profit Report & Smart Swing Trading Alerts - Улправда
How Ocular Therapeutix Inc. stock benefits from global expansion2025 Fundamental Recap & Community Verified Trade Alerts - Улправда
Will Ocular Therapeutix Inc. stock reach all time highs in 2025Trade Risk Assessment & Stepwise Swing Trade Plans - ulpravda.ru
Ocular Therapeutix (NASDAQ:OCUL) Stock Price Down 4.3%What's Next? - MarketBeat
Assessing Ocular Therapeutix (OCUL) Valuation After Accelerated FDA Filing Plan for AXPAXLI in Wet AMD - Sahm
Ocular Therapeutix stock could see 45% upside if trial succeeds, TD Cowen says - Investing.com Canada
RBC Capital Adjusts Ocular Therapeutix Price Target to $24 From $17, Maintains Outperform Rating - marketscreener.com
Ocular Therapeutix prepares NDA submission for wet AMD drug - MSN
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates - sharewise.com
Avoiding Lag: Real-Time Signals in (OCUL) Movement - news.stocktradersdaily.com
Ocular Therapeutix Inc. (OCUL) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
H.C. Wainwright Lifts Ocular Therapeutix, Inc. (OCUL) Price Target Following Intravitreal Implant FDA Submission - Insider Monkey
15 Best Biotech Stocks to Buy According to Wall Street Analysts - Insider Monkey
Chardan Capital Maintains Ocular Therapeutix (OCUL) Buy Recommendation - Nasdaq
Ocular Therapeutix (OCUL) Hits 4-Year High on Axpaxli NDA Application - Insider Monkey
EyePoint Pharmaceuticals (EYPT) Maintains Positive Outlook Amid Competitive Dynamics - GuruFocus
Is Ocular Therapeutix Inc a good long term investmentAnalyst Downgrades & Big Gains Low Investment - earlytimes.in
(OCUL) Stock Soars on Accelerated Wet AMD NDA – Price, Forecast & Risk Analysis as of December 9, 2025 - ts2.tech
Ocular Therapeutix's (OCUL) "Buy" Rating Reaffirmed at Chardan Capital - MarketBeat
Chardan Capital Maintains Buy Rating on OCUL with $21 Price Targ - GuruFocus
Ocular Therapeutix plans for NDA submission of AXPAXLI for wet AMD - Eyes On Eyecare
Ocular Therapeutix: Not So Fast On The Single-Trial Bet (Rating Downgrade) (NASDAQ:OCUL) - Seeking Alpha
Ocular Therapeutix stock price target raised to $30 by RBC on wAMD trial outlook - Investing.com Canada
Ocular Therapeutix stock hits 52-week high at 14.79 USD By Investing.com - Investing.com Canada
HC Wainwright & Co. Maintains Ocular Therapeutix (OCUL) Buy Recommendation - Nasdaq
2.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):